Prof. Dr. Helga Rübsamen-Schaeff

Prof. Rübsamen-Schaeff, a chemist by training, started her career as Scientific and Executive Director of an academic institution, the Chemotherapeutical Research Institute Georg-Speyer-Haus in Frankfurt with a focus on cancer research (tyrosine kinases) and HIV. In 1994, she joined Bayer as Head of Virological Research and later heading Bayer´s whole Infectious Disease Discovery as SVP.

In 2006 she founded the company AiCuris and lead it as CEO from 2006 until 2015. AiCuris Anti-Infective Cures GmbH is dedicated to the research and development of drugs against infectious diseases (viruses and multi-resistant bacteria). The first drug from AiCuris´ pipeline (licensed to MSD in 2012) was approved by the FDA in 2017, a great achievement for a young biotech company. The drug is licensed for the prevention of cytomegalovirus infections in patients, who received stem cell transplants in many legislations worldwide.

Presently, Prof. Rübsamen-Schaeff is a member of AiCuris ´Supervisory Board, a member of the Board of Partners of E. Merck KG and Chair of Merck´s Research Council as well as a member of the Supervisory Boards of Merck KGaA and 4SC AG. She is a member of the National Academy of Sciences of Germany, Leopoldina, received the Innovation Price by the President of the State of Germany in 2018 and the Löffler-Frosch Medal by the Gesellschaft für Virologie in 2020.